 ARCA biopharma Inc NASDAQ: ABIO announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the 160-patient trial, both doses of rNAPc2 demonstrated a treatment benefit. 